– BERMUDA, Hamilton – Roivant Sciences Ltd., an innovative biopharmaceutical company focused on developing promising drug candidates to improve the lives of patients and their families, has expanded its Board of Directors through the appointment of Patrick Machado as its second independent director. Prior to joining the board of Roivant Sciences, Mr. Machado was a co-founder of Medivation and served as its Chief Financial Officer from 2004 to 2014. He also served as a director of Medivation through September 2016.
“We are delighted to welcome Patrick Machado to our board,” said Vivek Ramaswamy, Founder and Director of Roivant Sciences. “Roivant will benefit greatly from Pat’s judgment and experience, including helping to build one of the most admired biotech companies of the past decade. I look forward to working with Pat and the rest of our team to build Roivant as a biopharmaceutical company of the future.”
“I am impressed with the diverse drug pipeline that Roivant has built in a short period of time, and I admire the company’s relentless focus on improving the lives of patients by creating a more efficient drug development model,” said Mr. Machado. “I am excited to work with the Roivant team in the years ahead.”
About Patrick Machado
Mr. Machado was a co-founder of Medivation, Inc., where he served as Chief Financial Officer for over a decade, from 2004 to 2014. He was also Chief Business Officer at Medivation from 2009 to 2014 and served on its Board of Directors from 2014 to 2016. Mr. Machado also serves on the boards of directors of other biopharmaceutical companies. He graduated from Santa Clara University summa cum laude with a BA in German and a BS in Economics, and received his JD from Harvard Law School.
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates with the potential to improve the lives of patients and their families. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the broader healthcare system.
Roivant delivers R&D solutions to its industry partners by helping them unlock value from their pipelines and realize the full potential of their research by completing the product development cycle. Roivant’s clinical development pipeline spans multiple therapeutic areas through strategic alliances, collaborations, and partnerships with academic institutions and pharmaceutical companies, including Takeda Pharmaceuticals, Eisai, GlaxoSmithKline, Vertex Pharmaceuticals, Duke University, and Cincinnati Children’s Hospital.
Roivant Sciences Ltd. is the majority controlling shareholder of Axovant Sciences Ltd. (NYSE: AXON) and a significant minority shareholder of Arbutus Biopharma Corporation (NASDAQ: ABUS).
For more information : http://www.roivant.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.